Akili Achieves Primary Efficacy Endpoint in Pediatric ADHD Pivotal Trial
Company Completes Large Multi-Center, Randomized, Controlled Study of Novel Digital Medicine and Plans Regulatory Filing BOSTON, Mass – December 4, 2017 – Akili Interactive (“Akili” or “Company”), an affiliate of PureTech Health (PRTC.L), today announced top-line results from the Company’s STARS-ADHD pivotal study of its lead investigational digital medicine, AKL-T01, in pediatric attention-deficit/hyperactivity disorder (ADHD). In a randomized, […]